USA flag logo/image

An Official Website of the United States Government

PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
81534
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
A072-142-0602
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PLX PHARMA, INC.
8285 EL RIO HOUSTON, TX -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: PC-NSAIDs: Gastrointestinal-safe and potent anti-inflammatory drugs
Agency / Branch: DOD / ARMY
Contract: W81XWH-08-C-0025
Award Amount: $729,991.00
 

Abstract:

We have developed a novel class of phosphatidylcholine (PC)-associated nonsteroidal antiinflammatory drugs (NSAIDs) to treat inflammation and pain with reduced GI side-effects. In Phase I studies using a number of in vitro systems monitoring the activity and threshold of nociceptive fibers under basal conditions and after exposure to inflammatory mediators, we demonstrated that a number of PC-NSAIDs were more effective than the unmodified drugs in reducing the activity of pain sensory nerves. Interestingly, preliminary analysis of in vitro primary human osteoblasts suggest that PC-NSAIDs may have favorable effects on bone remodeling compared with unmodified NSAIDs Based upon these studies, we propose to investigate in Phase II the therapeutic actions of the most effective PC-NSAID we have identified, Indomethacin-PC (vs. unmodified indomethacin) in rodent models of joint and nerve inflammation, post-operative incisional pain (to both mechanical and thermal stimulation) and bone healing. We also propose to evaluate the GI toxicity of the test NSAIDs in the above in vivo model systems to confirm Indomethacin-PC's superior GI safety. The parenteral and oral formulations of Indomethacin-PC will be optimized by the scientists at PLx Pharma in close consultation with our industrial advisors and our Co-investigators at the two University of Texas institutions.

Principal Investigator:

Upendra K. Marathi
Senior Vice President
7138421249
marathi@plxpharma.com

Business Contact:

Ronald R. Zimmerman
President & CEO
7138421249
ron.zimmerman@plxpharma.com
Small Business Information at Submission:

PLX PHARMA, INC.
8285 EL RIO, SUITE 130 HOUSTON, TX 77054

EIN/Tax ID: 141857610
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No